The Vantage Half-Year Review 2018 shows that biopharma small drug developers continue to hold all the cards, while young device makers suffer from a shrinking pool of buyers.
Our report offers analysis and expert commentary on M&A deals, venture financing, initial public offerings and FDA approval in the pharma and medtech sectors during the first half of 2018.
- Big biotech and big pharma stocks were largely shunned by investors over the first half of the year
- Demand for new biotech issues shows no sign of flagging, with a record $3.5bn raised in IPOs across western stock exchanges in the first half of 2018
- At the half year point 2018 is shaping up to have the lowest spend on medical device M&A since 2013. The total disclosed spend was less than $12bn, compared with $48.8bn a year ago
A Product Manager with expertise in pharma marketing and sales operations